Additional file 1: Figure S1. of Comparison of strain parameters in dyssynchronous heart failure between speckle tracking echocardiography vendor systems

Study flow diagram. Study flow diagram of the vendor comparison study. A total of 240 patients were included in six medical centres in the Netherlands. For GE EchoPac, 142 patients were included of which 123 echocardiograms were eligible for STE analysis. For Philips QLAB 88 of 98 echocardiograms were eligible for STE analysis. All echocardiograms were also analyzed with TomTec 2DCPA. Potential reasons for exclusions were: technical errors in the data format, low frame rate (<35 Hz), very poor image quality and irregular heart rhythm. MARC: markers of response to cardiac resynchronization therapy. (TIFF 2114 kb

Evolution of Left Ventricular End Systolic Volume over time of late non-responders.

<p>At six-month follow-up late non-responders showed a significant median decrease of left ventricular end systolic volume (LVESV) of 28%. However, at 14-month follow-up, LVESV almost returned to baseline values again.</p

Flow chart of responders and non-responders.

<p>Flow chart of responders and non-responders.</p

Baseline data of six-month responders, and stratified by late non-responders and stable responders.

<p>p-value between late non-responders and stable responders:</p><p>* = p < 0.05,</p><p>^# = p < 0.001</p><p>ACE: angiotensin-converting enzyme, BNP: B-type natriuretic peptide, IQR: Interquartile range, IVCD: Interventricular conduction delay, IVMD: Interventricular mechanical delay, LA: Left atrium, LBBB: Left bundle branch block, LVEDV: left ventricular end diastolic volume, LVEF: left ventricular ejection fraction, LVESV: left ventricular end systolic volume, NYHA: New York Heart Association, RA: Right atrium, RBBB: Right bundle branch block, RV: Right ventricle, SRS_sept: Systolic Rebound Stretch of the Septum</p><p>Baseline data of six-month responders, and stratified by late non-responders and stable responders.</p

MACE between 14–24 months after implantation in 6 and 14-month responders and non-responders.

<p>MACE: Major adverse cardiac events</p><p>MACE between 14–24 months after implantation in 6 and 14-month responders and non-responders.</p